Galectin-3 as a prognostic biomarker in haemodialysis patients with preserved or mildly reduced ejection fraction
In incident HD patients with an LVEF ≥40%, elevated galectin-3 was an independent predictor of CV death or acute HF events and provided incremental prognostic value beyond conventional clinical parameters and BNP. These findings support galectin-3 as a complementary biomarker for enhanced risk stratification in this population.
Authors
- Hyung‐Seok Lee (ORCID: https://orcid.org/0009-0007-3090-9126)
- Jwa-Kyung Kim (ORCID: https://orcid.org/0000-0002-7726-2143)
- Sung Gyun Kim (ORCID: https://orcid.org/0000-0002-5034-0527)
- Jung Nam An (ORCID: https://orcid.org/0000-0001-5108-1005)
- Sangil Min (ORCID: https://orcid.org/0000-0002-0688-0278)
- In‐Soo Kim (ORCID: https://orcid.org/0000-0003-2801-5514)
Institutions
- Sacred Heart Hospital (US)
- Hallym University Sacred Heart Hospital (KR)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1093/ckj/sfaf306
- Citations
- 1
- Primary Topic
- Galectins and Cancer Biology
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Hallym University